bluuebunny/crossref_metadata_2025_split huggingface dataset:
Systematic review and meta‐analysis of the pelvic organ prolapse and vaginal prolapse among the global population
Authors: Mudalige Tharanga , Pathiraja Vindya , Delanerolle Gayathri , Cavalini Heitor , Wu Shuqi , Taylor Julie , Kurmi Om , Elliot Kathryn , Hinchliff Sharron , Atkinson Carol , Potocnik Kristina , Briggs Paula , Saraswat Lucky , Kemp Helen Felicity , Eleje George , Hock Toh Teck , Benetti‐Pinto Cristina Laguna , Muhammad Irfan , Kareem Rabia , Bouchareb Yassine , Phiri Peter , Zhang Ruishu , Weng Yunfei , Aggarwal Ieera , Shi Jian Qing , Shetty Ashish , Litchfield Ian , Rathnayake Nirmala , Elneil Sohier 
Published: December 2024

AbstractBackgroundPelvic organ prolapse (POP) occurs when one or more pelvic organs (uterus, bowel, bladder or top of the vagina) descend from their normal position and bulge into the vagina. Symptoms include pelvic discomfort, fullness, and changes in bladder or bowel function. Treatment ranges from conservative approaches to surgery, depending on symptom severity. Surgical methods include vaginal wall repair, with or without hysterectomy, or via laparoscopic, robotic or open techniques. Common complications include bleeding, infection, and urinary or bowel dysfunction.MethodsA systematic review was conducted, and a protocol was registered with PROSPERO (CRD42022346051). Publications from 30 April 1980 to 30 April 2023 were retrieved from multiple databases. Data were analysed using random‐effects and common‐effects models with subgroup and sensitivity analyses.FindingsForty‐four studies met the inclusion criteria, with 29 studies used for meta‐analysis of vaginal prolapse surgery outcomes. Sixteen studies focused on patients who had undergone hysterectomy alongside prolapse repair.InterpretationPatients who underwent vaginal prolapse surgery with hysterectomy experienced higher operative and postoperative complication rates than those without hysterectomy. Increased risks included hospital readmission, POP recurrence and re‐operation. The review highlighted a lack of diversity in terms of ethnicity, age and comorbidity status, which are essential to fully understanding the impact of POP. Future research should focus on these underrepresented factors.
Monitoring of the Biotechnological Production of Dihydroxyacetone Using a Low‐Field 1H NMR Spectrometer
Authors: Mahler Lukas , Tasdemir Ebru , Nickisch‐Hartfiel Anna , Mayer Christian , Jaeger Martin 
Published: December 2024

ABSTRACTThe concept of sustainable production necessitates the utilization of waste and by‐products as raw materials, the implementation of biotechnological processes, and the introduction of automated real‐time monitoring for efficient use of resources. One example is the biocatalyzed conversion of the reusable by‐product glycerin by acetic acid bacteria to dihydroxyacetone (DHA), which is of great importance to the cosmetic industry. The application of compact spectrometers enables the rapid measurement of samples while simultaneously reducing the consumption of resources and energy. Yet, this approach requires comprehensive data preprocessing and, on occasion, multivariate data analysis. For the process monitoring of the production of DHA, a low‐field 1H nuclear magnetic resonance (NMR) spectrometer was implemented in on‐line mode. Small‐volume samples were taken from a bypass and transferred to the spectrometer by an autosampler. Complete analysis within minutes allowed real‐time process control. To this purpose, reliable automated spectral preprocessing preceded the creation of a univariate model. The model enabled the acquisition of process knowledge from chemical kinetics and facilitated the tracking of both substrate and product concentrations, requiring independent calibration. As a second multivariate approach, principal component analysis was utilized to monitor the process in a semi‐quantitative manner without the necessity for calibration. The results of this study are beneficial for real‐time monitoring applications with the objective of exerting control over the process in question while minimizing expenditure.
Project‐Based Learning in Bioprocess Engineering: MATLAB Software as a Tool for Industrial‐Scale Bioreactor Design
Authors: González‐Cortés José Joaquín , Cantero Domingo , Ramírez Martín 
Published: December 2024

ABSTRACTThe project‐based learning (PBL) methodology has proven to be a valuable pedagogical approach in engineering programs for decades. However, a significant gap remains in the application of such methodologies in the field of bioprocess engineering. This study addresses this gap by exploring the implementation and outcomes of innovative PBL methodology in the context of bioprocess engineering education. The educational innovation involved the study of a bioprocess at the industrial scale, which comprises the definition of the culture medium, the operational units of the process, the design of the bioreactor with the assistance of MATLAB software, and the performance of a techno‐economic analysis. The results over eight academic years (441 students) demonstrated consistently high average grades in case studies (8.9 ± 0.3 out of 10), indicating successful student navigation of PBL challenges. The students’ positive feedback highlighted the satisfaction and effectiveness of the methodology in promoting collaboration, enhancing comprehension, and preparing students for real‐world scenarios. Overall, this study provides valuable insights into the successful implementation of PBL in bioprocess engineering education, highlighting its potential for fostering active learning, practical skill development, and student engagement. These findings contribute to the growing body of literature on innovative pedagogical approaches in engineering education and underscore the importance of ongoing evaluation and refinement for enhancing student learning outcomes.
Mogamulizumab‐Associated Autoimmune Diseases: Insights From FAERS Database Analysis
Authors: Zhang Genshan , Zhang Haokun , Fu Jie , Cao Zhixin 
Published: December 2024

ABSTRACTBackgroundMogamulizumab is a monoclonal antibody targeting the C‐C chemokine receptor 4, used to treat T‐cell malignancies such as cutaneous T‐cell lymphoma, adult T‐cell leukemia/lymphoma, and peripheral T‐cell lymphoma. However, real‐world studies on mogamulizumab‐associated adverse events (AEs) are limited.MethodsDisproportionality analyses were performed to assess the safety profile of mogamulizumab based on data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database for the period spanning from October 2018 to December 2023. The research investigated demographic characteristics, the onset timing of AEs, and the safety implications associated with mogamulizumab use.ResultsA total of 1182 significant preferred terms were identified among the 3661 mogamulizumab‐associated AE reports collected from the FAERS database. The frequently reported AEs including rash, infusion‐related reaction, and pyrexia were in line with drug instruction. Notably, several unexpectedly significant AEs were also found, including pemphigoid (ROR = 5.69 [95% CI 1.83–17.66]), unstable angina (ROR = 20.56 [95% CI 8.54–49.5]), bulbar palsy (ROR = 238.36 [95% CI 75.22–755.31]), myositis (ROR = 12.65 [95% CI 5.67–28.19]), and various autoimmune diseases such as autoimmune hepatitis (ROR = 21.33 [95% CI 11.08–41.07]), myocarditis (ROR = 15.29 [95% CI 8.67–26.97]), glomerulonephritis (ROR = 22.49 [95% CI 7.24–69.9]), nephrotic syndrome (ROR = 7.63 [95% CI 2.46–23.67]), myasthenia gravis (ROR = 8.54 [95% CI 3.2–22.77]), and autoimmune thyroiditis (ROR = 11.81 [95% CI 3.8–36.68]).ConclusionThis study replicated previously identified AEs associated with mogamulizumab and uncovered additional signals of AEs, particularly emphasizing the risks associated with autoimmune diseases. It is essential to exercise vigilance in monitoring the occurrence of these AEs during the use of mogamulizumab in clinical practice.
LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis
Authors: Ke Zi‐Hao , Chen Ying , Yu Tao , Zhang Qi , Xiang Yan , Lu Kai‐Hua 
Published: December 2024

ABSTRACTBackgroundImmune biomarkers for non‐small‐cell lung cancer (NSCLC) are programmed death ligand 1 (PD‐L1) and tumor mutational burden (TMB). However, they cannot accurately predict the effectiveness of immunotherapy. Identifying appropriate biomarkers that can differentiate between beneficiary groups is imperative.MethodsWe identified lipoprotein receptor–related protein 1B (LRP1B) mutation as a potential biomarker for immunotherapy by analyzing clinical data, combined with bioinformatics analysis. The effects of LRP1B on ferroptosis were assessed using qRT‐PCR, Western blotting, CCK‐8 assay, and flow cytometry. The potential mechanism underlying the regulation of ferroptosis by LRP1B was elucidated using qRT‐PCR, Western blotting, ChIP, and dual‐luciferase reporter gene assays.ResultsThrough the collection and analysis of clinical data, we had established that LRP1B mutations are closely associated with immunotherapy. Bioinformatics analysis revealed significant differences in the expression levels of PD‐L1 and TMB between patients with LRP1B mutation and wild‐type patients in lung adenocarcinoma (LUAD). Furthermore, we observed that patients with LRP1B mutation in LUAD had significantly higher levels of tumor‐infiltrating lymphocytes (TILs) than wild‐type patients. In addition, we found that patients with LRP1B mutation in LUAD had significantly prolonged progression‐free survival (PFS) compared to wild‐type patients. However, the differences of PD‐L1 expression, TILs, and PFS were not observed in patients with LRP1B mutation in lung squamous cell carcinoma (LUSC). These findings provided strong evidence that LRP1B mutation was a potential biomarker for immunotherapy in LUAD. Moreover, our in vivo experiments indicated that knockdown of LRP1B enhanced the efficacy of mPD‐1, and mechanistic studies revealed that LRP1B regulated the sensitivity of cells to ferroptosis by modulating the expression of SLC7A11 through altering the phosphorylation level of STAT3. Further analysis revealed that LRP1B knockdown promoted immunotherapy in vivo.ConclusionsOur results confirmed that LRP1B affected the efficacy of immunotherapy by modulating the sensitivity of NSCLC cells to ferroptosis. LRP1B mutations represent a highly promising immunotherapeutic biomarker for NSCLC.
Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas
Authors: Ziaziaris William A. , Lim Christopher S. H. , Sioson Loretta , Gill Anthony J. , Samra Jaswinder S. , Sahni Sumit , Mittal Anubhav 
Published: December 2024

ABSTRACTIntroductionIntraductal papillary mucinous neoplasms (IPMNs) are diverse premalignant tumors of the pancreas. They progress stepwise from adenoma to carcinoma and offer an opportunity for intervention prior to malignant transformation into pancreatic ductal adenocarcinoma (PDAC). The current study aimed to identify differentially expressed genes (DEGs) in invasive PDAC‐associated IPMN vs. noninvasive IPMN to understand the potential molecular changes involved in malignant transformation of IPMN into PDAC.Materials and MethodsArchived tissue and data from 12 patients with histologically proven invasive PDAC arising from IPMN specimens were assessed. Gene expression analysis was performed on RNA extracted from macro‐dissected tissue specimens using the NanoString nCounter PanCancer Progression assay. Statistical and pathway analysis was performed using SPSS v28 and Ingenuity Pathway Analysis, respectively.ResultsA total of 159 genes had significantly (p < 0.05, q < 0.05) different expression in PDAC arising from IPMN compared with that from IPMN alone (91 overexpressed and 68 underexpressed). Interestingly, 14 of top 10 over‐ and underexpressed genes were predicted to translate secretory proteins, with SignalP scores approaching 1. A number of differential canonical pathways (e.g., LXR/RXR activation pathway, glycolysis I gluconeogenesis I, and hepatic fibrosis) and potential upstream regulators (e.g., TGFB1, THBS2, etc.) were also identified.ConclusionA differential gene expression profile between PDAC arising from IPMN and IPMN alone was identified. Pathway analysis identified potential mechanisms involved in malignant transformation of IPMN to PDAC.
Sequential Dual Guide Catheter Technique for Chronic Total Occlusion Interventions in Patients With Prior Coronary Artery Bypass Graft Surgery
Authors: Al‐Ogaili Ahmed , Chu A. J. , Sandoval Yader , Brilakis Emmanouil S. 
Published: December 2024

ABSTRACTTriple arterial access is sometimes necessary for complete visualization of the collateral circulation and distal vessel anatomy, and to facilitate the retrograde approach in complex chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in patients with prior coronary artery bypass surgery (CABG) and multiple sources of collaterals. We present two CTO PCI cases in prior CABG patients with complex occlusions supplied by multiple sources of collaterals for which a “sequential dual guide technique” was used, reducing the number of necessary arterial access points from three to two.
A Case of BRASH Syndrome Presenting With Refractory Hyperkalemia Requiring Intermittent Hemodialysis
Authors: Khadka Bikash , Poudel Saroj , Khanal Kishor , Regmi Ashim , Ghimire Anup , Shrestha Sharad , KC Shirish , Nepal Rohini ,   Doctors on Wheels (DOW)
Published: December 2024

ABSTRACTBRASH syndrome characterized by bradycardia, renal dysfunction, atrioventricular nodal blockade (AVNB), shock, and hyperkalemia presents diagnostic and management challenges due to its complex pathophysiology and varied clinical presentations. We describe a 90‐year‐old woman with a history of multiple comorbidities who was on beta blockers bisoprolol for heart failure, presented with shock, refractory hyperkalemia along with bradycardia that required intermittent hemodialysis. Initial management involved aggressive hyperkalemia medical therapy and fluid resuscitation, with subsequent consideration of renal replacement therapy hemodialysis following collaboration with a multidisciplinary team, including cardiology and nephrology specialists. Despite aggressive medical management for hyperkalemia, some cases of BRASH syndrome may remain challenging to treat, requiring intermittent hemodialysis highlighting the need for further research and understanding of this complex clinical entity to improve treatment outcomes.
Spontaneous Tumor Lysis Syndrome in an Undifferentiated Uterine Sarcoma: A Case Report and Review of the Literature
Authors: Valizadeh Zahra , Farshchi Parisa 
Published: December 2024

ABSTRACTTumor lysis syndrome (TLS), as an oncologic emergency, may rarely occur in patients with solid organ neoplasms and without previous cancer therapy. Physicians should be highly aware of the possibility of TLS, with special attention in patients having bulky tumors, irrespective of recent treatment with cytotoxic agents for its prompt prevention and treatment.
Giant Primary Choledocholithiasis: A Rare Case Report and Comprehensive Review of Literature
Authors: Lamichhane Samiksha , KC Suraj , Mishra Nishant , Devkota Shritik , Kumar Abhijeet , Gupta Rakesh Kumar 
Published: December 2024

ABSTRACTCholedocholithiasis is the second most common complication of gallstone disease. Giant primary choledocholithiasis is a rare occurrence. Ultrasonography is the initial mode of imaging, and endoscopic ultrasound is considered superior to other modalities. Endoscopic retrograde cholangiopancreatography can be used for stone extraction. Other treatment modalities include laparoscopic or open common bile duct (CBD) exploration. Many institutions in underdeveloped countries still practice open CBD exploration. Factors such as larger stone diameter, edema of the CBD, and the presence of multiple lithiasis can influence the treatment approach. In this article we are presenting a case of 62 years‐old‐female with no any known comorbidities had presented to emergency with severe upper quadrant pain and giant choledocholithiasis was diagnosed in ultrasound and computed tomography scan with no other features of complications and patient successfully underwent open CBD exploration with intraoperative choledochoscopy and primary closure.
Red Room Temperature Phosphorescence in Non‐Aromatic Carbonized Polymer Dots
Authors: Kang Chunyuan , Tao Songyuan , Yang Fan , Zheng Chengyu , Li Xiaoyu , Yang Bai 
Published: December 2024

AbstractAchieving red organic room temperature phosphorescence (RTP) remains a significant challenge, especially in a non‐aromatic system. Herein, red RTP with emission at 605 and 645 nm is achieved through inducing and confining carboxyl dimer association (CDA), a unique hydrogen‐bonded coupling red phosphorescence unit, in non‐aromatic carbonized polymer dots (CPDs). The CPDs are synthesized via microwave method by using polyacrylic acid (PAA), succinic acid (SA), and traces of phosphoric acid as precursors. Small molecule SA can flexibly enter the polymer cluster of PAA and pair with the isolated carboxyl groups to form CDA. The intrinsic local carbonized structure formed in CPDs can effectively stabilize CDA to achieve red RTP. The red afterglow can last for 1 s to naked eye, and the corresponding lifetimes for emission at 605 and 645 nm were 61 and 45 ms, respectively, after 365 nm excitation off. This work not only reported the non‐aromatic red organic RTP materials for the first time, but also explored CPDs as an effective platform for achieving such non‐aromatic long‐wavelength RTP.
Gold‐Catalyzed Access to Pyrrolo‐ and (Aryl)Indolo‐Fused Phenazines
Authors: Hüßler Christopher , Dietl Martin C. , Scherr Matthias , Blaum Immanuel E. , Stuntebeck Hanno , Trogemann Lea , Schmidt Sophia , Kahle Justin , Krämer Petra , Rominger Frank , Rudolph Matthias , Hashmi A. Stephen K. 
Published: December 2024

AbstractNovel fused phenazines were synthesized through a combination of gold‐catalyzed hydroamination and cascade cyclization reactions towards azaacenes. In total, 30 new compounds were synthesized and investigated with respect to their structural and optoelectronic properties. In solution, these targets exhibit strong green to red emission, with quantum yields of up to 60 %. The emission wavelength can be finely adjusted by the choice of solvent due to their solvatochromic behavior, as demonstrated with a representative example.
Holistic Management of Wastewater Pollution Through Biological Treatment: A Sustainable Future
Authors: Chatterjee Bidisha , Baruah Stootee , Chatterjee Deepsikha , Dey Sharadia , Mitra Arup Kumar 
Published: December 2024

ABSTRACTThe global population is increasing at an elevated speed leading to the expansion of urbanization at the cost of environmental degradation, especially aquatic ecosystem pollution due to the enhanced discharge of wastewater. These aquatic ecosystems are primarily polluted by potentially toxic elements, polyaromatic hydrocarbons, dyes, plastics, pesticides, organic compounds, and molecules present in fertilizers, household wastes, industrial effluents, and sewage discharge. The enhanced deterioration of water bodies has led to the search for natural solutions for a sustainable ecosystem. The utilization of the natural microbial flora of the aquatic ecosystem for remediation, more popularly known as bioremediation, is of global interest because of its cost‐effectiveness and eco‐friendly approach. Bioremediation can be broadly categorized into bacterial remediation, mycoremediation, and phytoremediation and is more commonly studied for soil pollution. However, in this review, we discuss bioremediation techniques and mechanisms with respect to water pollution. Aquatic microbes utilize the toxic components present in wastewater as a substrate for their own metabolism by acting as a biologically active methylator or by chemical alteration of the toxicants into less harmful products, thus degrading the toxic environmental pollutants into nontoxic products thereby eliminating their detrimental effects. Microalgae used in phytoremediation also help to elevate the dissolved oxygen level in the aquatic ecosystem thereby reducing the probability of eutrophication. This review represents the study of diverse pollutants remediation and a method involving microbial consortia in a bioreactor for optimum efficacy at minimum cost.
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC‐1
Authors: Cai Zhen , Xia Zhongjun , He Ai‐Li , Dong Yu‐Jun , Wang Yafei , Liao Aijun , Song Yang , Song MM Juanjuan , Uhlar Clarissa , Chastain Katherine , Watkins Latisha , Luo Xinchao , Huang Lin , Niu Zhuolu , Quijano Cardé Natalia A. , Guo Yue , Xu Hongmei , Verona Raluca I. , Zhou Longen , Li Jingyun , Fu Weijun , Niu Ting , Du Juan 
Published: December 2024

AbstractIntroductionTeclistamab, the first approved B‐cell maturation antigen‐directed bispecific antibody for treatment of triple‐class exposed relapsed/refractory multiple myeloma, demonstrated deep, durable responses with a manageable safety profile in the pivotal MajesTEC‐1 cohort (NCT03145181/NCT04557098). Efficacy, safety, and pharmacokinetics from the MajesTEC‐1 China cohort are reported.MethodsPatients received teclistamab 1.5 mg/kg subcutaneously weekly after step‐up dosing; patients could switch to less frequent dosing with continued response.ResultsIn the China cohort (N = 26; median age, 66 years; median prior lines of therapy, 5) 15‐month median follow‐up, overall response rates, very good partial response or better, and complete response or better (≥CR) were 76.9%, 76.9%, and 57.7%, respectively. Median time to first response and ≥CR were 1.4 and 6.3 months, respectively; among patients with ≥CR and have available MRD samples, MRD negativity was achieved in 14/15 (93.3%) patients. Median duration of response, progression‐free survival, and overall survival were not reached; 12‐month duration of response, progression‐free survival, and overall survival rates were 78.5%, 68.0%, and 83.5%, respectively. The safety profile was consistent with the pivotal cohort. Although infections occurred in 96.2% of patients, incidence decreased over time with six patients experiencing infections for >12 to 18 months. There were no discontinuations because of adverse events and no dose reductions. Ten patients switched to less frequent dosing. Teclistamab serum concentrations were consistent with the pivotal cohort, with a slightly lower mean pharmacokinetics profile.ConclusionsTeclistamab demonstrated efficacy and safety profiles in the China cohort consistent with the pivotal cohort, supporting teclistamab as a promising treatment option for triple‐class exposed relapsed/refractory multiple myeloma in China.